Skip to content

Cardiovascular and metabolic risk in obstructive sleep apnoea (OSA)

Cardiovascular and metabolic risk in obstructive sleep apnoea (OSA)

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600117191
Enrollment
Unknown
Registered
2026-01-21
Start date
2026-01-31
Completion date
Unknown
Last updated
2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obstructive sleep apnea (OSA)

Interventions

Control group:None

Sponsors

Affiliated Hospital of Southwest Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Age > 18 years old, gender not limited; 2.OSA Group (Group 1): Diagnosed with moderate to severe OSA via polysomnography, with an apnea-hypopnea index (AHI) >=15 times/hour (moderate: 15-30 times/hour; severe: >30 times/hour). 3.Control group (Group 2): No OSA (AHI < 5 times/hour), matched with the OSA group for age (± 3 4 5 years) and sex. 4.Both groups must meet the following requirements: no continuous positive airway pressure (CPAP) therapy for at least 3 days prior to the assessment; and voluntarily participate and sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1. Patients with malignant tumors or receiving related treatment; 2. Current use of ß-blockers (may affect catecholamine detection); 3. patients with phenylketonuria (PKU); 4. Patients with severe chronic liver/kidney disease and heart failure (New York Heart function class ?-?); 5. Pregnant or lactating women; 6. Other conditions that the investigator considers may affect the study results (e.g., mental illness inability to cooperate with the examination). (Use a checklist to make a list of conditions that could affect the efficacy or safety assessment of the study, such as other treatments contrary to the inclusion criteria, coexisting conditions, and pregnancy.

Design outcomes

Primary

MeasureTime frame
Difference in core serum biomarkers (NT-proBNP, hs-TnI, fasting glucose, lipid profile, insulin, cortisol/aldosterone, catecholamines, liver/kidney function markers) between OSA and control groups;

Countries

China

Contacts

Public ContactTian Gang

Affiliated Hospital of Southwest Medical University

tiangang@swmu.edu.cn+86 18244362063

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026